Company Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:38 2024-12-04 am EST			5-day change	1st Jan Change
90.10 ^CHF	-3.14%		-2.86%	+6.16%

Dec. 04	Novartis cannot block generic of best-selling heart drug, US appeals court says	RE
Dec. 04	HSBC Downgrades Novartis to Reduce, Price Target is $95	MT

Business description: Novartis AG

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:

- oncology (29.9%);

- immunology (17.2%);

- cardiovascular, renal and metabolic diseases (14.1%);

- neuroscience (8.9%).

The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.

At the end of 2023, Novartis AG had 33 production sites worldwide.

Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Number of employees: 76,057

Sales by Activity: Novartis AG

Fiscal Period: December	2019	2020	2021	2022	2023
Innovative Medicines	39.59B	40.82B	43.97B	43.37B	46.66B
Sandoz	9.94B	9.89B	9.87B	9.48B	-
Corporate (Including Eliminations)	-847M	-813M	-964M	-1.02B	-

See all business segments

Geographical breakdown of sales: Novartis AG

Fiscal Period: December	2019	2020	2021	2022	2023
United States	16.28B	16.48B	16.82B	17.65B	17.96B
Other	21.1B	19.04B	20.81B	20.05B	15.87B
Germany	4.12B	4.52B	4.87B	4.28B	3.37B
China	-	2.57B	3.05B	3.13B	3.27B
Japan	2.66B	2.8B	2.68B	2.2B	1.92B
France	2.44B	2.44B	2.52B	2.26B	1.75B
Switzerland	848M	800M	873M	970M	1.31B

See all geographic segments

Managers: Novartis AG

Director	Title	Age	Since
Vasant Narasimhan CEO	Chief Executive Officer	48	2018-01-31
Harry Werner Kirsch DFI	Director of Finance/CFO	59	2013-04-23
Shreeram Aradhye CTO	Chief Tech/Sci/R&D Officer	62	2022-05-15
Klaus Moosmayer CMP	Compliance Officer	56	2018-11-30
Steffen Lang COO	Chief Operating Officer	57	2022-04-03

See NOVARTIS AG governance

Members of the board: Novartis AG

Manager	Title	Age	Since
Charles Sawyers BRD	Director/Board Member	65	2012-12-31
Bill Winters BRD	Director/Board Member	63	2012-12-31
Hans Jörg Reinhardt CHM	Chairman	68	2012-12-31
Nancy Andrews BRD	Director/Board Member	65	2014-12-31
Liz Doherty BRD	Director/Board Member	67	2015-12-31
Ton Büchner BRD	Director/Board Member	59	2015-12-31
Frans van Houten BRD	Director/Board Member	64	2017-02-27
Patrice Bula BRD	Director/Board Member	68	2019-02-27
Bridgette Heller BRD	Director/Board Member	62	2020-02-27
Simon Moroney BRD	Director/Board Member	65	2020-02-27

Composition of the Board of Directors

Shareholders: Novartis AG

Name	Equities	%	Valuation
NOVARTIS AG 6.625 %	145,083,991	6.625 %	15 738 M CHF
Sandoz Family Foundation 4.070 %	89,135,960	4.070 %	9 669 M CHF
UBS Asset Management Switzerland AG 3.123 %	68,391,910	3.123 %	7 419 M CHF
Amundi Asset Management SA (Investment Management) 0.3485 %	7,632,562	0.3485 %	828 M CHF
State Street Global Advisors Ltd. 0.2145 %	4,696,568	0.2145 %	509 M CHF

Name	Equities	%	Valuation
Dodge & Cox 0.5581 %	12,221,876	0.5581 %	1 325 M CHF
PRIMECAP Management Co. 0.5483 %	12,008,055	0.5483 %	1 302 M CHF
DFA Australia Ltd. 0.3508 %	7,681,951	0.3508 %	833 M CHF
Eaton Vance Management 0.3190 %	6,984,872	0.3190 %	757 M CHF
Loomis, Sayles & Co. LP 0.2635 %	5,769,638	0.2635 %	625 M CHF

Name	Equities	%	Valuation
MFS International (UK) Ltd. -	2,572,907	-	280 M CHF
LUKB Expert Fondsleitung AG -	82,294	-	9 M CHF
Swiss Rock Asset Management AG -	19,614	-	2 M CHF
N.F.U. Mutual Unit Managers Ltd. -	18,420	-	2 M CHF
Skyblue Fund Managers (Pty) Ltd. -	6,000	-	652 041 CHF

List of NOVARTIS AG shareholders

Holdings: Novartis AG

Name	Equities	%	Valuation
NOVARTIS AG 6.63%	145,083,991	6.63%	15,738,265,936 $
SANDOZ GROUP AG 2.99%	12,886,900	2.99%	586,445,576 $
NOVARTIS INDIA LIMITED 70.68%	17,450,680	70.68%	221,500,085 $
THIRD HARMONIC BIO, INC. 5.87%	2,642,762	5.87%	36,443,688 $
ERASCA, INC. 4.36%	12,307,692	4.36%	31,876,922 $
OCULIS HOLDING AG 4.10%	1,713,521	4.10%	29,438,291 $
MOLECULAR PARTNERS AG 4.31%	1,739,130	4.31%	10,297,615 $
PRECISION BIOSCIENCES, INC. 5.72%	413,581	5.72%	3,540,253 $

Company details: Novartis AG

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com

Group companies: Novartis AG

Name	Category and Sector
Novartis Healthcare Pvt Ltd. Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar.	Pharmaceuticals: Major
Novartis Investment Ltd.
Novartis Holding AG Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment.	Financial Conglomerates
Novartis International AG Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Services, Inc. is an innovative medicines company that aims to improve and extend people's lives by reimagining medicine to empower patients, healthcare professionals, and societies in the face of serious diseases. The company's medicines reach over 250 million people worldwide. Novartis Services, Inc. offers a range of products and services, including the Zolgensma® Managed Access Program (gMAP), which provides information for patients and their caregivers about clinical trial recruitment, managed access programs (MAPs), funding opportunities for patient organizations, side effects reporting, and the development of a new healthcare system. The program also provides resources for physicians and other healthcare professionals such as clinical trial recruiting information, grant funding, congresses, country-level research reporting, medical education programs, international collaboration with hospitals, as well as a database of publications. Novartis Services, Inc. is committed to sustainability and ethical business practices and holds itself to high standards. The company is based in Cambridge, MA and was founded in 2002.	Pharmaceuticals: Major

See all subsidiaries

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
NOVARTIS AG	-3.14%	-2.86%	+4.60%	+22.47%	210B
ELI LILLY AND COMPANY	+2.03%	+5.28%	+41.69%	+237.91%	732B
NOVO NORDISK A/S	-0.29%	+4.92%	+12.68%	+121.50%	488B
JOHNSON & JOHNSON	-1.24%	-3.17%	-5.29%	-5.59%	367B
ABBVIE INC.	-2.78%	-3.62%	+22.41%	+48.47%	321B
MERCK & CO., INC.	-0.47%	-1.70%	-3.51%	+38.22%	258B
ROCHE HOLDING AG	-0.31%	+0.48%	+3.00%	-29.97%	231B
ASTRAZENECA PLC	-2.87%	-0.49%	+2.08%	+27.95%	212B
AMGEN INC.	-0.02%	-0.65%	+2.10%	+37.45%	150B
PFIZER, INC.	-1.29%	-2.32%	-13.83%	-53.51%	145B
Average	-0.82%	+0.42%	+6.59%	+44.49%	311.19B
Weighted average by Cap.	-0.46%	+1.14%	+13.33%	+83.04%